Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, Finland, Netherlands, Switzerland, Sweden, Taiwan, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
Metrics to compare | BAVAc | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBAVAcPeersSector | |
---|---|---|---|---|
P/E Ratio | 12.6x | −4.4x | −0.5x | |
PEG Ratio | −0.33 | 0.00 | 0.00 | |
Price/Book | 1.1x | 2.9x | 2.6x | |
Price / LTM Sales | 2.2x | 3.9x | 3.0x | |
Upside (Analyst Target) | - | 94.8% | 54.7% | |
Fair Value Upside | Unlock | 18.4% | 9.3% | Unlock |